Stocktoria
UroGen Pharma Ltd. URGN
UroGen Pharma Ltd. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109.8M | $90.4M | $82.7M | $64.4M | $48.0M | $11.8M | $18,000 | $1.1M | $8.2M | $17.5M |
| Gross profit | $97.3M | $81.5M | $73.4M | $56.7M | $42.9M | $10.8M | $18,000 | -$675,000 | $7.6M | $17.5M |
| R&D expense | $67.1M | $57.1M | $45.6M | $52.9M | $47.6M | $47.3M | $49.3M | $36.9M | $18.7M | — |
| SG&A expense | $155.1M | $121.2M | $93.3M | $82.8M | $87.5M | $90.2M | $60.2M | — | — | — |
| Operating income | -$124.9M | -$96.8M | -$65.5M | -$79.0M | -$92.3M | -$126.7M | -$109.5M | -$77.2M | -$19.9M | $798,000 |
| Income tax | $78,000 | $2.8M | $3.9M | $1.8M | $1.4M | $3.4M | — | $125,000 | $19,000 | — |
| Net income | -$153.5M | -$126.9M | -$102.2M | -$109.8M | -$110.8M | -$128.5M | -$105.1M | -$75.7M | -$20.0M | -$1.9M |
| Operating cash flow | -$162.4M | -$96.8M | -$76.4M | -$87.6M | -$84.9M | -$105.9M | -$71.0M | -$37.3M | -$9.6M | $4.2M |
| Free cash flow | -$162.7M | -$97.1M | -$76.6M | -$87.8M | -$85.6M | -$107.1M | -$71.3M | -$37.9M | -$9.8M | $3.5M |
| Cash & equivalents | $110.7M | $172.0M | $95.0M | $55.4M | $44.4M | $52.9M | $49.7M | $101.3M | $37.0M | $21.4M |
| Inventory | $16.5M | $9.2M | $5.7M | $4.3M | $4.8M | $2.0M | — | — | $316,000 | $105,000 |
| Total assets | $200.5M | $285.7M | $178.3M | $135.6M | $119.7M | $122.0M | $202.4M | $103.6M | $75.5M | $23.1M |
| Total liabilities | $305.9M | $294.5M | $243.5M | $225.0M | $111.3M | $25.6M | $22.1M | $13.5M | $7.0M | $6.7M |
| Shareholders' equity | -$105.5M | -$8.8M | -$65.2M | -$89.4M | $8.4M | $96.4M | $180.3M | $90.1M | $68.5M | $16.3M |
Growth · year-over-year · Revenue CAGR 22.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +21.4% | +9.3% | +28.5% | +34.0% | +307.2% | +65450.0% | -98.4% | -86.2% | -53.5% | — |
| Free cash flow growth | — | — | — | — | — | — | — | — | -381.6% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.